White matter pathology in phenylketonuria

Molecular Genetics and Metabolism

Volumn 99, Issue SUPPL., 2010, Pages

  Anderson, Peter J ^a,b   Leuzzi, Vincenzo ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Diffusion tensor imaging; Magnetic resonance imaging; Neuropsychological functioning; Phenylketonuria; White matter abnormality

Indexed keywords

PHENYLALANINE 4 MONOOXYGENASE;

ARTICLE; BRAIN CORTEX; DIET RESTRICTION; DIET THERAPY; EARLY INTERVENTION; FRONTAL CORTEX; FUNCTIONAL DISEASE; HISTOPATHOLOGY; HUMAN; METABOLIC REGULATION; MYELINATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENYLKETONURIA; PRIORITY JOURNAL; WHITE MATTER;

EID: 72249095815     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.10.005     Document Type: Article

References (91)

1. Huttenlocher P.R. The neuropathology of phenylketonuria: human and animal studies. Eur. J. Pediatr. 159 (2000) S102-S106
2. Perez-Duenas B., Pujol J., Soriano-Mas C., Ortiz H., Artuch R., Vilaseca M.A., and Campistol J. Global and regional volume changes in the brains of patients with phenylketonuria. Neurology 66 (2006) 1074-1078
3. Pfaendner N.H., Reuner G., Pietz J., Jost G., Rating D., Magnotta V.A., Mohr A., Kress B., Sartor K., and Hahnel S. MR imaging-based volumetry in patients with early-treated phenylketonuria. AJNR Am. J. Neuroradiol. 26 (2005) 1681-1685
4. Dyer C.A. Pathophysiology of phenylketonuria. Ment. Retard. Dev. Disabil. Res. Rev. 5 (1999) 104-112
5. Malamud N. Neuropathology of phenylketonuria. J. Neuropathol. Exp. Neurol. 25 (1966) 254-268
6. Dyer C.A., Kendler A., Philibotte T., Gardiner P., Cruz J., and Levy H.L. Evidence for central nervous system glial cell plasticity in phenylketonuria. J. Neuropathol. Exp. Neurol. 55 (1996) 795-814
7. Hommes F.A., Eller A.G., and Taylor E.H. Turnover of the fast components of myelin and myelin proteins in experimental hyperphenylalaninaemia. Relevance to termination of dietary treatment in human phenylketonuria. J. Inherit. Metab. Dis. 5 (1982) 21-27
8. Hommes F.A., and Moss L. Myelin turnover in hyperphenylalaninaemia. A re-evaluation with the HPH-5 mouse. J. Inherit. Metab. Dis. 15 (1992) 243-251
9. Levy H.L., Lobbreqt D., Barnes P.D., and Poussaint T.Y. Maternal phenylketonuria: magnetic resonance imaging of the brain in offspring. J. Pediatr. 128 (1996) 770-775
10. Koch R., Verma S., and Gilles F.H. Neuropathology of a 4-month-old infant born to a woman with phenylketonuria. Dev. Med. Child Neurol. 50 (2008) 230-233
11. Villasana D., Butler I.J., Williams J.C., and Roongta S.M. Neurological deterioration in adult phenylketonuria. J. Inherit. Metab. Dis. 12 (1989) 451-457
12. Thompson A.J., Smith I., Brenton D., Youl B.D., Rylance G., Davidson D.C., Kendall B., and Lees A.J. Neurological deterioration in young adults with phenylketonuria. Lancet 336 (1990) 602-605
13. Pearsen K.D., Gean-Marton A.D., Levy H.L., and Davis K.R. Phenylketonuria: MR imaging of the brain with clinical correlation. Radiology 177 (1990) 437-440
14. Weglage J., Schuierer G., Kurlemann G., Bick R., and Ullrich K. Different degrees of white matter abnormalities in untreated phenylketonurics: findings in magnetic resonance imaging. J. Inherit. Metab. Dis. 16 (1993) 1047-1048
15. Anderson P.J., Wood S.J., Francis D.E., Coleman L., Warwick L., Casanelia S., Anderson V.A., and Boneh A. Neuropsychological functioning in children with early-treated phenylketonuria: impact of white matter abnormalities. Dev. Med. Child Neurol. 46 (2004) 230-238
16. Bick U., Fahrendorf G., Ludolph A.C., Vassallo P., Weglage J., and Ullrich K. Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging. Eur. J. Pediatr. 150 (1991) 185-189
17. Bick U., Ullrich K., Stober U., Moller H., Schuierer G., Ludoph A.C., Oberwittler C., Weglage J., and Wendel U. White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings. Eur. J. Pediatr. 152 (1993) 1012-1020
18. Cleary M.A., Walter J.H., Wraith J.E., Jenkins J.P., Alani S.M., Tyler K., and Whittle D. Magnetic resonance imaging of the brain in phenylketonuria. Lancet 344 (1994) 87-90
19. Leuzzi V., Tosetti M., Montanaro D., Carducci C., Artiola C., Carducci C., Antonozzi I., Burroni M., Carnevale F., Chiarotti F., Popolizio T., Giannatempo G.M., D'Alesio V., and Scarabino T. The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study. J. Inherit. Metab. Dis. 30 (2007) 209-216
20. Leuzzi V., Trasimeni G., Gualdi G.F., and Antonozzi I. Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients. J. Inherit. Metab. Dis. 18 (1995) 624-634
21. Lou H.C., Toft P.B., Andresen J., Mikkelsen I., Olsen B., Guttler F., Wieslander S., and Henriksen O. An occipito-temporal syndrome in adolescents with optimally controlled hyperphenylalaninemia. J. Inherit. Metab. Dis. 15 (1992) 687-695
22. Pietz J., Kreis R., Schmidt H., Meyding-Lamade U.K., Rupp A., and Boesch C. Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. Radiology 201 (1996) 413-420
23. Shaw D.W., Maravilla K.R., Weinberger E., Garretson J., Trahms C.M., and Scott C.R. MR imaging of phenylketonuria. AJNR Am. J. Neuroradiol. 12 (1991) 403-406
24. Thompson A.J., Tillotson S., Smith I., Kendall B., Moore S.G., and Brenton D.P. Brain MRI changes in phenylketonuria. Associations with dietary status. Brain 116 (1993) 811-821
25. Leuzzi V., Gualdi G.F., Fabbrizi F., Trasimeni G., Di Biasi C., and Antonozzi I. Neuroradiological (MRI) abnormalities in phenylketonuric subjects: clinical and biochemical correlations. Neuropediatrics 24 (1993) 302-306
26. Toft P.B., Lou H.C., Krageloh-Mann I., Andresen J., Guttler F., Guldberg P., and Henriksen O. Brain magnetic resonance imaging in children with optimally controlled hyperphenylalaninaemia. J. Inherit. Metab. Dis. 17 (1994) 575-583
27. Weglage J., Bick U., Schuierer G., Pietsch M., Sprinz A., Zass R., and Ullrich K. Progression of cerebral white matter abnormalities in early treated patients with phenylketonuria during adolescence. Neuropediatrics 28 (1997) 239-240
28. Cleary M.A., Walter J.H., Wraith J.E., White F., Tyler K., and Jenkins J.P. Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. J. Pediatr. 127 (1995) 251-255
29. Walter J.H., White F., Wraith J.E., Jenkins J.P., and Wilson B.P. Complete reversal of moderate/severe brain MRI abnormalities in a patient with classical phenylketonuria. J. Inherit. Metab. Dis. 20 (1997) 367-369
30. Leuzzi V., Fois D., Carducci C., Antonozzi I., and Trasimeni G. Neuropsychological and neuroradiological (MRI) variations during phenylalanine load: protective effect of valine, leucine, and isoleucine supplementation. J. Child Neurol. 12 (1997) 338-340
31. Anderson P.J., Wood S.J., Francis D.E., Coleman L., Anderson V., and Boneh A. Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels?. Dev. Neuropsychol. 32 (2007) 645-668
32. Leuzzi V., Bianchi M.C., Tosetti M., Carducci C.L., Carducci C.A., and Antonozzi I. Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria. J. Inherit. Metab. Dis. 23 (2000) 563-570
33. Moller H.E., Weglage J., Wiedermann D., and Ullrich K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J. Cereb. Blood Flow Metab. 18 (1998) 1184-1191
34. Novotny E.J., Avison M.J., Herschkowitz N., Petroff O.A., Prichard J.W., Seashore M.R., and Rothman D.L. In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy. Pediatr. Res. 37 (1995) 244-249
35. Pietz J., Kreis R., Boesch C., Penzien J., Rating D., and Herschkowitz N. The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo 1H magnetic resonance spectroscopy. Pediatr. Res. 38 (1995) 657-663
36. Moller H.E., Vermathen P., Ullrich K., Weglage J., Koch H.G., and Peters P.E. In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment. Neuropediatrics 26 (1995) 199-202
37. Moller H.E., Weglage J., Wiedermann D., Vermathen P., Bick U., and Ullrich K. Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo. Brain Res. 778 (1997) 329-337
38. Rupp A., Kreis R., Zschocke J., Slotboom J., Boesch C., Rating D., and Pietz J. Variability of blood-brain ratios of phenylalanine in typical patients with phenylketonuria. J. Cereb. Blood Flow Metab. 21 (2001) 276-284
39. Koch R., Moats R., Guttler F., Guldberg P., and Nelson Jr. M. Blood-brain phenylalanine relationships in persons with phenylketonuria. Pediatrics 106 (2000) 1093-1096
40. Weglage J., Wiedermann D., Denecke J., Feldmann R., Koch H.G., Ullrich K., Harms E., and Moller H.E. Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann. Neurol. 50 (2001) 463-467
41. Moller H.E., Weglage J., Bick U., Wiedermann D., Feldmann R., and Ullrich K. Brain imaging and proton magnetic resonance spectroscopy in patients with phenylketonuria. Pediatrics 112 (2003) 1580-1583
42. Moats R.A., Koch R., Moseley K., Guldberg P., Guttler F., Boles R.G., and Nelson Jr. M.D. Brain phenylalanine concentration in the management of adults with phenylketonuria. J. Inherit. Metab. Dis. 23 (2000) 7-14
43. Jones S.J., Turano G., Kriss A., Shawkat F., Kendall B., and Thompson A.J. Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. J. Neurol. Neurosurg. Psychiatry 59 (1995) 260-265
44. Leuzzi V., Rinalduzzi S., Chiarotti F., Garzia P., Trasimeni G., and Accornero N. Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations. J. Inherit. Metab. Dis. 21 (1998) 351-364
45. Hajek M., Hejcmanova L., and Pradny J. Proton in vivo spectroscopy of patients with hyperphenylalaninemia. Neuropediatrics 24 (1993) 111-112
46. Dezortova M., Hajek M., Tintera J., Hejcmanova L., and Sykova E. MR in phenylketonuria-related brain lesions. Acta Radiol. 42 (2001) 459-466
47. Johannik K., Van Hecke P., Francois B., Marchal G., Smet M.H., Jaeken J., Breysem L., Wilms G., and Baert A.L. Localized brain proton NMR-spectroscopy in young-adult phenylketonuria patients. Magn. Reson. Med. 31 (1994) 53-57
48. Phillips M.D., McGraw P., Lowe M.J., Matthews V.P., and Hainline B.E. Diffusion-weighted imaging of white matter abnormalities in patients with phenylketonuria. AJNR Am. J. Neuroradiol. 22 (2001) 1583-1586
49. Vermathen P., Robert-Tissot L., Pietz J., Lutz T., Boesch C., and Kreis R. Characterization of white matter alterations in phenylketonuria by magnetic resonance relaxometry and diffusion tensor imaging. Magn. Reson. Med. 58 (2007) 1145-1156
50. Scarabino T., Popolizio T., Tosetti M., Montanaro D., Giannatempo G.M., Terlizzi R., Pollice S., Maiorana A., Maggialetti N., Carriero A., Leuzzi V., and Salvolini U. Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion. Radiol. Med. 114 (2009) 461-474
51. Ding X.Q., Fiehler J., Kohlschutter B., Wittkugel O., Grzyska U., Zeumer H., and Ullrich K. MRI abnormalities in normal-appearing brain tissue of treated adult PKU patients. J. Magn. Reson. Imaging 27 (2008) 998-1004
52. Kono K., Okano Y., Nakayama K., Hase Y., Minamikawa S., Ozawa N., Yokote H., and Inoue Y. Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter. Radiology 236 (2005) 630-636
53. Sirrs S.M., Laule C., Madler B., Brief E.E., Tahir S.A., Bishop C., and MacKay A.L. Normal-appearing white matter in patients with phenylketonuria: water content, myelin water fraction, and metabolite concentrations. Radiology 242 (2007) 236-243
54. Paus T., Zijdenbos A., Worsley K., Collins D.L., Biumenthal J., Giedd J.N., Rapoport J.L., and Evans A.C. Structural maturation of neural pathways in children and adolescents: in vivo study. Science 283 (1999) 1908-1911
55. Filley C. The Behavioral Neurology of Cerebral White Matter (2001), Oxford University Press, New York
56. Araujo G.C., Christ S.E., Steiner R.D., Grange D.K., Nardos B., McKinstry R.C., and White D.A. Response monitoring in children with phenylketonuria. Neuropsychology 23 (2009) 130-134
57. Brumm V.L., Azen C., Moats R.A., Stern A.M., Broomand C., Nelson M.D., and Koch R. Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review. J. Inherit. Metab. Dis. 27 (2004) 549-566
58. Channon S., Mockler C., and Lee P. Executive functioning and speed of processing in phenylketonuria. Neuropsychology 19 (2005) 679-686
59. Leuzzi V., Pansini M., Sechi E., Chiarotti F., Carducci C., Levi G., and Antonozzi I. Executive function impairment in early-treated PKU subjects with normal mental development. J. Inherit. Metab. Dis. 27 (2004) 115-125
60. White D.A., Nortz M.J., Mandernach T., Huntintong K., and Steiner R.D. Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria. Neuropsychology 15 (2001) 221-229
61. Banich M.T., Passarotti A.M., White D.A., Nortz M.J., and Steiner R.D. Interhemispheric interaction during childhood: II. Children with early-treated phenylketonuria. Dev. Neuropsychol. 18 (2000) 53-71
62. Diamond A. Phenylalanine levels of 6-10 mg/dl may not be as benign as once thought. Acta Paediatr. Suppl. 407 (1994) 89-91
63. Diamond A., Prevor M.B., Callender G., and Druin D.P. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr. Soc. Res. Child Dev. 62 (1997) i-v 1-208
64. Gourovitch M., Craft S., Dowton S.B., Ambrose P., and Sparta S. Interhemispheric transfer in children with early-treated phenylketonuria. J. Clin. Exp. Neuropsychol. 16 (1994) 393-404
65. Huijbregts S., de Sonneville L., Licht R., Sergeant J., and van Spronsen F. Inhibition of prepotent responding and attentional flexibility in treated phenylketonuria. Dev. Neuropsychol. 22 (2002) 481-499
66. Huijbregts S.C., de Sonneville L.M., Licht R., van Spronsen F.J., Verkerk P.H., and Sergeant J.A. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 40 (2002) 7-15
67. Smith M.L., Klim P., Mallozzi E., and Hanley W.B. Test of the frontal-specificity hypothesis in the cognitive performance of adults with phenylketonuria. Dev. Neuropsychol. 12 (1996) 327-342
68. Smith M.L., Klim P., and Hanley W.B. Executive function in school-aged children with phenylketonuria. J. Dev. Phys. Disabil. 12 (2000) 317-332
69. Stemerdink N.B.A., van der Molen M.W., Kalverboer A.F., van der Meere J.J., Huisman J., de Jong L.W., Slijper F.M.E., Verker P.H., and van Spronsen F.J. Prefrontal dysfunction in early and continuously treated phenylketonuria. Dev. Neuropsychol. 16 (1999) 29-57
70. Welsh M.C., Pennington B.F., Ozonoff S., Rouse B., and McCabe E.R. Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev. 61 (1990) 1697-1713
71. White D.A., Nortz M.J., Mandernach T., Huntington K., and Steiner R.D. Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria. Neuropsychology 15 (2001) 221-229
72. White D.A., Nortz M.J., Mandernach T., Huntington K., and Steiner R.D. Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria. J. Int. Neuropsychol. Soc. 8 (2002) 1-11
73. Pietz J., Dunckelmann R., Rupp A., Rating D., Meinck H.M., Schmidt H., and Bremer H.J. Neurological outcome in adult patients with early-treated phenylketonuria. Eur. J. Pediatr. 157 (1998) 824-830
74. Weglage J., Pietsch M., Funders B., Koch H.G., and Ullrich K. Neurological findings in early treated phenylketonuria. Acta Paediatr. 84 (1995) 411-415
75. Burlina A., Bonafe L., Ferrari V., Suppliej A., Zacchello F., and Burlina A.P. Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment. J. Inherit. Metab. Dis. 23 (2000) 313-316
76. Feldmann R., Denecke J., Pietsch M., Grenzebach M., and Weglage J. Phenylketonuria: no specific frontal lobe-dependent neuropsychological deficits of early-treated patients in comparison with diabetics. Pediatr. Res. 51 (2002) 761-765
77. Schmidt E., Rupp A., Burgard P., Pietz J., Weglage J., and de Sonneville L. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level. J. Clin. Exp. Neuropsychol. 16 (1994) 681-688
78. Schmidt E., Burgard P., and Rupp A. Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria. Eur. J. Pediatr. 155 (1996) S82-S86
79. Weglage J., Pietsch M., Funders B., Koch H.G., and Ullrich K. Deficits in selective and sustained attention processes in early treated children with phenylketonuria-result of impaired frontal lobe functions?. Eur. J. Pediatr. 155 (1996) 200-204
80. McKean C. The effects of high phenylalanine concentrations on serotonin and catecholamine metabolism in the human brain. Brain Res. 47 (1972) 469-476
81. Tam S., and Roth R. Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their function?. Biochem. Pharmacol. 51 (1997) 441-453
82. Diamond A., Ciaramitaro V., Donner E., Djali S., and Robinson M.B. An animal model of early-treated PKU. J. Neurosci. 14 (1994) 3072-3082
83. Chido L.A., Bannon M.J., Grace A.A., Roth R.H., and Bunney B.S. Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors of mesocortical dopamine neurons. Neuroscience 12 (1984) 1-16
84. Sawaguchi T., and Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251 (1991) 947-950
85. Robbins T. Chemical neuromodulation of frontal-executive functions in humans and other animals. Brain Res. 133 (2000) 130-138
86. Griffiths P., Campbell R., and Robinson P. Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test. J. Inherit. Metab. Dis. 21 (1998) 125-135
87. Luciana M., Sullivan J., and Nelson C.A. Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev. 72 (2001) 1637-1652
88. Mazzocco M.M., Nord A.M., Van Doorninck W., Greene C.L., Kovar C.G., and Pennington B.F. Cognitive development among children with early-treated phenylketonuria. Dev. Neuropsychol. 10 (1994) 133-151
89. Weglage J., Pietsch M., Denecke J., Sprinz A., Feldmann R., Grenzebach M., and Ullrich K. Regression of neuropsychological deficits in early-treated phenylketonurics during adolescents. J. Inherit. Metab. Dis. 22 (1999) 693-705
90. Smith M.L., Hanley W.B., Clarke J.T., Klim P., Schoonheyt W., Austin V., and Lehotay D.C. Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. Arch. Dis. Child. 78 (1998) 116-121
91. Pietz J., Meyding-Lamade U.K., and Schmidt H. Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency. Eur. J. Pediatr. 155 (1996) S69-S73